A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: ITCA 650 60 mcg/day
DRUG: sitagliptin

Sponsor

Intarcia Therapeutics